Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CTSD | P07339 | 1/20 | 0.30 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
| ▸ | CTSB | P07858 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22021971 | 0.78 | CA12 (0.32) | CA12CA14CA1CA7CA2 | |
| SCHEMBL22059570 | 0.77 | CA12 (0.33) | MEN1KMT2ACA12CA14CA1 | |
| SCHEMBL16374978 | 0.77 | ALDH1A1 (0.41) | MEN1KMT2ACA12CA14 | |
| SCHEMBL18510032 | 0.76 | DGAT1 (0.34) | MEN1KMT2ACA12CA14CA1 | |
| SCHEMBL7176207 | 0.76 | DGAT1 (0.34) | CA12CA14CA1CA7CA2 | |
| SCHEMBL20087392 | 0.74 | CA12 (0.53) | CA12CA14CA1CA7CA2 | |
| SCHEMBL16766811 | 0.74 | HDAC6 (0.41) | CA12CA1CA2NR1D1 | |
| SCHEMBL13981283 | 0.73 | CYP2D6 (0.38) | CA12CA14CA1CA7CA2 | |
| SCHEMBL6629116 | 0.73 | CA12 (0.50) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL27420033 | 0.73 | NR1D1 (0.38) | CA12CA14CA1CA7CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108473426-B | Cyclic amine derivative and medical use thereof | 东丽株式会社 | 2021-09-07 | — | — | CN | disclosed |
| US-10881649-B2 | Therapeutic agent or preventive agent for alopecia areata | TORAY INDUSTRIES, INC. (JP) | 2021-01-05 | — | — | US | disclosed |
| US-10881649-B2 | Therapeutic agent or preventive agent for alopecia areata | TORAY INDUSTRIES, INC. (JP) | 2021-01-05 | — | — | US | disclosed |
| US-20200215046-A1 | THERAPEUTIC AGENT OR PREVENTIVE AGENT FOR ALOPECIA AREATA | TORAY INDUSTRIES, INC. (JP) | 2020-07-09 | — | — | US | disclosed |
| US-20200215046-A1 | THERAPEUTIC AGENT OR PREVENTIVE AGENT FOR ALOPECIA AREATA | TORAY INDUSTRIES, INC. (JP) | 2020-07-09 | — | — | US | disclosed |
| EP-3409660-B1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES (JP) | 2020-07-01 | — | — | EP | disclosed |
| EP-3659602-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR ALOPECIA AREATA | Toray Industries, Inc. (JP) | 2020-06-03 | — | — | EP | disclosed |
| CN-110913859-A | Therapeutic or prophylactic agent for round alopecia | 东丽株式会社 | 2020-03-24 | — | — | CN | disclosed |
| US-10364222-B2 | Cyclic amine derivative and medical use thereof | TORAY INDUSTRIES, INC. (JP) | 2019-07-30 | — | — | US | disclosed |
| US-10364222-B2 | Cyclic amine derivative and medical use thereof | TORAY INDUSTRIES, INC. (JP) | 2019-07-30 | — | — | US | disclosed |
| WO-2019022235-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR ALOPECIA AREATA | 東レ株式会社 | 2019-01-31 | — | — | WO | disclosed |
| US-20180370916-A1 | CYCLIC AMINE DERIVATIVE AND MEDICAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2018-12-27 | — | — | US | disclosed |
| EP-3409660-A1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Toray Industries, Inc. (JP) | 2018-12-05 | — | — | EP | disclosed |
| WO-2017131156-A1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | 東レ株式会社 | 2017-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200215046-A1 | THERAPEUTIC AGENT OR PREVENTIVE AGENT FOR ALOPECIA AREATA | RORA, RORB, RORC | MEN1 4292/4885KMT2A 418/4885CA12 647/4885 |
| US-20180370916-A1 | CYCLIC AMINE DERIVATIVE AND MEDICAL USE THEREOF | RORC, RORB, HRH3 | MEN1 3267/4885KMT2A 960/4885CA12 2609/4885 |
| US-10364222-B2 | Cyclic amine derivative and medical use thereof | RORC, RORB, HRH3 | MEN1 3267/4885KMT2A 960/4885CA12 2609/4885 |
| US-10881649-B2 | Therapeutic agent or preventive agent for alopecia areata | RORA, RORB, RORC | MEN1 4292/4885KMT2A 418/4885CA12 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.